Reports

Sale

Hospital-Acquired Infection Treatment Market

Global Hospital-Acquired Infection Treatment Market Share, Size, Growth: By Products and Services: Sterilization, Cleaning and Disinfection Products, Protective Barriers, Endoscope Reprocessing Products; By Infection Type: Hospital-acquired Pneumonia, Others; By Application; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Global Hospital-Acquired Infection Treatment Market Outlook

The hospital-acquired infection treatment market size was estimated to be worth USD 15.95 billion in 2023. The market is expected to rise at a growth rate of 4.5% in the forecast period of 2024-2032 to attain a market size of nearly USD 23.66 billion by 2032. Novel therapy launches and approvals are expected to fuel the market growth during the forecast period.

 

hospital acquired infection treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Hospital-Acquired Infection: Type, Causes, Diagnosis, and Treatment

Hospital-acquired infection are infections that are acquired by the hospital or any other healthcare facility or from any healthcare professional, including doctors and nurses, among others, during the course of the treatment. The hospital-acquired infection are also referred to as healthcare-associated infections and nosocomial infections.

 

There are different types of healthcare-associated infections depending on the mode of entry of the causative pathogen and the type of the pathogen. According to the Centers for Disease Control and Prevention, nearly 1.7 million healthcare-associated infections were reported in the United States.

 

There are several modes of transmission attributing to the widespread of hospital-acquired infection, such as contact transmission, droplet transmission, airborne transmission, common vehicle transmission, and vector-borne transmission.

 

Nosocomial infections can be prevented by following several preventative steps and measures including sanitation, sterilisation, isolation, and frequent sanitation habits. The treatment for these types of infections is solely based on the eradication of the causative agents, responsible for causing the disease.

 

There are different antibiotics approved for eradicating or slowing the growth of the gram-positive strains of Staphylococcus aureus and gram-negative strains of Acinetobacter baumannii. Several other novel therapeutic medications are under clinical development for providing better therapeutic and diagnostic care.

 

According to the hospital-acquired infection treatment market research report, the market can be categorised into the following segments:

 

hospital acquired infection treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Product and Services

  • Sterilization
    • Sterilization Products
      • Heat Sterilization Equipment
      • Low-Temperature Sterilization Equipment
      • Radiation Sterilization Equipment
      • Other Sterilization Equipment
    • Contract Sterilization Services
    • Sterilization Consumables and Accessories
  • Cleaning and Disinfection Products
    • Disinfectants
    • Disinfectors Equipment
    • Others
  • Protective Barriers
  • Endoscope Reprocessing Products

 

Market Breakup by Infection Type

  • Hospital-acquired Pneumonia
  • Bloodstream Infections
  • Surgical Site Infections
  • Gastrointestinal Infections
  • Urinary Tract Infections (UTIs)
  • Others

 

Market Breakup by Application

  • Drug-Resistance Testing
  • Disease Testing
  • Others

 

Market Breakup by End User

  • Hospitals and ICUs
  • Ambulatory Surgical and Diagnostic Centres
  • Nursing Homes and Maternity Centres

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

hospital acquired infection treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Scenario

The growth of the hospital-acquired infection treatment market is primarily driven by the rising incidence and prevalence of healthcare-associated infections. This is further stimulated by the growing cases of chronic disorders and surgeries, which require prolonged hospital stays and thus will increase the risk of acquiring nosocomial infections. Additionally, the technological advancements in the devices implemented for infection control are also expected to bolster the market growth during the forecast period.

 

The hospital-acquired infection treatment market is augmented by the higher rate of surgical site infections, which is anticipated to increase the demand for the products and devices to manage hospital-acquired infection, and henceforth propel the market growth. According to the Centers for Disease Control and Prevention, nearly 20,000 surgical site infections were reported in the United States, thus accounting for significant market growth.

 

With extensive research and innovation, there is the discovery of novel therapeutic products by the key players and the major pharmaceutical companies. For example, Esco discovered a new sterilization device, incorporating a Cell Culture CO2 Incubator with High Heat Sterilization (CCL-HHS). The discovery of these devices will aid the eradication of the microorganisms contaminating the marketplace. Such product launches and approvals are expected to boost the market expansion in the forthcoming period.

 

Among the products segment, the disinfectants segment is anticipated to dominate the hospital-acquired infection treatment market owing to the increasing prevalence of chronic disorders, hospital-acquired infection, rising awareness, and the growing number of surgical interventions. Several reports suggested that nearly half of nosocomial infections occur in the intensive care units. The application of surface disinfectants aid in the prevention of these infections and will boost the market growth.

 

North America Accounts for the Largest Share

North America is anticipated to account for the largest share of the hospital-acquired infection treatment market due to the growth in hospital stays with the increase in the number of chronic diseases and surgeries. This can be attributed to the rising number of hospital admissions, that too for an extended period. Further, this will also increase the chances of hospital-acquired infection and will bolster the market development.

 

Therapeutic Landscape

The hospital-acquired infection are generally treated with the help of medications and other home remedies. The diagnosis of the infection is performed using the help of blood tests, X-rays, and other diagnostic tests based on the symptoms. 

 

Antibiotics are the most prescribed medications used for the treatment of nosocomial infections. The antibiotics act against the bacteria responsible for causing the infections by killing them or slowing their growth. 

 

The two bacteria species that are likely to infect patients are Gram-positive strains of Staphylococcus aureus and Gram-negative strains of Acinetobacter baumannii. The frequent hospital-acquired infection are of the surgical site, urinary tract, and several types of pneumonia. An alternative treatment strategy used for the management of these infections is irradiation incorporating ultraviolet C.

 

In case the infection is caused by any foreign device such as a catheter, the doctor may remove it for the appropriate medical period. Home remedies such as the administration of a balanced diet, high fluid intake, and proper rest are the additional treatment measures that will assist in faster and better recovery.

 

Clinical Trials Landscape

With the increasing prevalence of chronic disorders, the risk of hospital-acquired infection also increases. For better diagnosis and treatment, clinical researchers and scientists are working on discovering novel therapeutic interventions that will aid in the management of non-cosmical infections.

 

Vir Biotechnology, a key market player, is evaluating the potential of its new therapies, VIR-3434 and VIR-2218, that could be considered as a functional cure for chronic hepatitis virus infection. This type of infection is categorised as healthcare-associated, and if successfully passed, it will help in bolstering the growth of the hospital-acquired infection treatment market.

 

Ascentage Pharma, another major pharmaceutical company, is performing clinical trials for the novel drug, which is anticipated to act by inhibiting the apoptosis protein antagonist in Chinese patients suffering from chronic hepatitis virus, which can be acquired from hospitals and other medical centres.

 

With time, the bacterial strains develop microbial resistance against the available antibiotics, thus the scientists are working on developing novel treatment options for managing resistant pneumonia. The newer treatment methods and faster approvals by the regulatory authorities are expected to boost the hospital-acquired infection treatment market growth during the forecast period.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the hospital-acquired infection treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

 

  • 3M
  • Belimed AG
  • Ecolab Inc.
  • Fortive
  • Getinge AB
  • Bayer AG
  • Danaher
  • Novartis AG
  • Merck & Co., Inc.
  • Abbott
  • Pfizer Inc.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Products and Services
  • Infection Type
  • Application
  • End User
  • Region
Breakup by Products and Services
  • Sterilization
  • Cleaning and Disinfection Products
  • Protective Barriers
  • Endoscope Reprocessing Products
Breakup by Infection Type
  • Hospital-acquired Pneumonia
  • Bloodstream Infections
  • Surgical Site Infections
  • Gastrointestinal Infections
  • Urinary Tract Infections (UTIs)
  • Others
Breakup by Application
  • Drug-Resistance Testing
  • Disease Testing
  • Others
Breakup by End User
  • Hospitals and ICUs
  • Ambulatory Surgical and Diagnostic Centres
  • Nursing Homes and Maternity Centres
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • 3M
  • Belimed AG
  • Ecolab Inc.
  • Fortive
  • Getinge AB
  • Bayer AG
  • Danaher
  • Novartis AG
  • Merck & Co., Inc.
  • Abbott
  • Pfizer Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
2    Research Methodology
3    Executive Summary
4    Hospital-Acquired Infection Overview

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Current Scenario Evaluation and Regulatory Framework
    6.1    Emerging Therapies and Clinical Trials
    6.2    Patent Landscape 
        6.2.1    Patent Overview
            6.2.1.1    Patent Status and Expiry
            6.2.1.2    Timelines from Drug Development to Commercial Launch
            6.2.1.3    New Drug Application
                6.2.1.3.1    Documentation and Approval Process
    6.3    Cost of Treatment
    6.4    Regulatory Framework
        6.4.1    Regulatory Overview
            6.4.1.1    US FDA
            6.4.1.2    EU EMA
            6.4.1.3    INDIA CDSCO
            6.4.1.4    JAPAN PMDA
            6.4.1.5    Others
7    Challenges and Unmet Needs
    7.1    Treatment Pathway Challenges
    7.2    Compliance and Drop-Out Analysis
    7.3    Awareness and Prevention Gaps
8    Global Hospital-Acquired Infection Treatment Market   
    8.1    Global Hospital-Acquired Infection Treatment Market Overview
    8.2    Global Hospital-Acquired Infection Treatment Market Analysis 
        8.2.1    Market Overview
            8.2.1.1    Global Hospital-Acquired Infection Treatment Market Historical Value (2017-2023) 
            8.2.1.2    Global Hospital-Acquired Infection Treatment Market Forecast Value (2024-2032)
        8.2.2    Global Hospital-Acquired Infection Treatment Market by Products and Services
            8.2.2.1    Market Overview
                8.2.2.1.1    Sterilization
                    8.2.2.1.1.1    Sterilization Products
                        8.2.2.1.1.1.1    Heat Sterilization Equipment
                        8.2.2.1.1.1.2    Low-Temperature Sterilization Equipment
                        8.2.2.1.1.1.3    Radiation Sterilization Equipment
                        8.2.2.1.1.1.4    Other Sterilization Equipment
                    8.2.2.1.1.2    Contract Sterilization Services
                    8.2.2.1.1.3    Sterilization Consumables and Accessories
                8.2.2.1.2    Cleaning and Disinfection Products
                    8.2.2.1.2.1    Disinfectants
                    8.2.2.1.2.2    Disinfectors Equipment
                    8.2.2.1.2.3    Others
                8.2.2.1.3    Protective Barriers
                8.2.2.1.4    Endoscope Reprocessing Products
        8.2.3    Global Hospital-Acquired Infection Treatment Market by Infection Type
            8.2.3.1    Market Overview
                8.2.3.1.1    Hospital-acquired Pneumonia
                8.2.3.1.2    Bloodstream Infections
                8.2.3.1.3    Surgical Site Infections
                8.2.3.1.4    Gastrointestinal Infections
                8.2.3.1.5    Urinary Tract Infections (UTIs)
                8.2.3.1.6    Others
        8.2.4    Global Hospital-Acquired Infection Treatment Market by Application
            8.2.4.1    Market Overview
                8.2.4.1.1    Drug-Resistance Testing
                8.2.4.1.2    Disease Testing
                8.2.4.1.3    Others
        8.2.5    Global Hospital-Acquired Infection Treatment Market by End User
            8.2.5.1    Market Overview
                8.2.5.1.1    Hospitals and ICUs
                8.2.5.1.2    Ambulatory Surgical and Diagnostic Centres
                8.2.5.1.3    Nursing Homes and Maternity Centres
        8.2.6    Global Hospital-Acquired Infection Treatment Market by Region
            8.2.6.1    Market Overview
                8.2.6.1.1    North America
                8.2.6.1.2    Europe
                8.2.6.1.3    Asia Pacific
                8.2.6.1.4    Middle East and Africa
                8.2.6.1.5    Latin America
9    North America  Hospital-Acquired Infection Treatment Market
    9.1    Market Share by Country
    9.2    United States of America
        9.2.1    Historical Trend (2017-2023)
        9.2.2    Forecast Trend (2024-2032)
    9.3    Canada
        9.3.1    Historical Trend (2017-2023)
        9.3.2    Forecast Trend (2024-2032)
10    Europe Hospital-Acquired Infection Treatment Market
    10.1    Market Share by Country
    10.2    United Kingdom
        10.2.1    Historical Trend (2017-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    Germany
        10.3.1    Historical Trend (2017-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    France
        10.4.1    Historical Trend (2017-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Italy
        10.5.1    Historical Trend (2017-2023)
        10.5.2    Forecast Trend (2024-2032)
    10.6    Others
11    Asia Pacific Hospital-Acquired Infection Treatment Market
    11.1    Market Share by Country
    11.2    China
        11.2.1    Historical Trend (2017-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    Japan
        11.3.1    Historical Trend (2017-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    India
        11.4.1    Historical Trend (2017-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    ASEAN
        11.5.1    Historical Trend (2017-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Australia
        11.6.1    Historical Trend (2017-2023)
        11.6.2    Forecast Trend (2024-2032)
    11.7    Others
12    Latin America Hospital-Acquired Infection Treatment Market
    12.1    Market Share by Country
    12.2    Brazil
        12.2.1    Historical Trend (2017-2023)
        12.2.2    Forecast Trend (2024-2032)
    12.3    Argentina
        12.3.1    Historical Trend (2017-2023)
        12.3.2    Forecast Trend (2024-2032)
    12.4    Mexico
        12.4.1    Historical Trend (2017-2023)
        12.4.2    Forecast Trend (2024-2032)
    12.5    Others
13    Middle East and Africa Hospital-Acquired Infection Treatment Market
    13.1    Market Share by Country
    13.2    Saudi Arabia
        13.2.1    Historical Trend (2017-2023)
        13.2.2    Forecast Trend (2024-2032)
    13.3    United Arab Emirates
        13.3.1    Historical Trend (2017-2023)
        13.3.2    Forecast Trend (2024-2032)
    13.4    Nigeria
        13.4.1    Historical Trend (2017-2023)
        13.4.2    Forecast Trend (2024-2032)
    13.5    South Africa
        13.5.1    Historical Trend (2017-2023)
        13.5.2    Forecast Trend (2024-2032)
    13.6    Others
14    Global Hospital-Acquired Infection Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces Model 
    14.4    Key Demand Indicators 
    14.5    Key Price Indicators 
    14.6    Industry Events, Initiatives, and Trends 
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    3M
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2    Belimed AG
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Ecolab Inc.
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Fortive
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    Getinge AB
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    Bayer AG
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    Danaher
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    Novartis AG
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    Merck & Co., Inc.
        15.9.1    Company Overview
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications
    15.10    Abbott
        15.10.1    Company Overview
        15.10.2    Product Portfolio
        15.10.3    Demographic Reach and Achievements
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications
    15.11    Pfizer Inc.
        15.11.1    Company Overview
        15.11.2    Product Portfolio
        15.11.3    Demographic Reach and Achievements
        15.11.4    Mergers and Acquisitions
        15.11.5    Certifications
16    Hospital-Acquired Infection Treatment Market- Drug Distribution Model (Additional Insight)
    16.1    Overview 
    16.2    Potential Distributors 
    16.3    Key Parameters for Distribution Partner Assessment
17    Payment Methods (Additional Insight)
    17.1    Government Funded
    17.2    Private Insurance
    17.3    Out-of-Pocket

 

*Additional insights provided are customizable as per client requirements.

Key Questions Answered in the Report

The market size is likely to reach a value of USD 15.95 billion in 2023.

The market is likely to grow at a CAGR of 4.5% during the forecast period of 2024-2032 to attain a value of USD 23.66 billion by 2032.

Based on the product and services, the market is segmented into sterilisation, cleaning and disinfection products, protective barriers, and endoscope reprocessing products.

Based on the infection type, the market is categorised into hospital-acquired Pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, and urinary tract infections, among others.

Based on the application, the market is segmented into drug-resistance testing and disease testing, among others.

Based on the end user, the market is categorised into hospitals and ICUs, ambulatory surgical and diagnostic centres, nursing homes and maternity centres.

The different regions in the market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.

The key companies involved in the market are 3M, Belimed AG, Ecolab Inc., Fortive, Getinge AB, Bayer AG, Danaher, Novartis AG, Merck & Co., Inc., Abbott, and Pfizer Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER